RESUMEN
ABSTRACT: Malignant atrophic papulosis/Köhlmeier-Degos disease was first described in 1941 by Köhlmeier in an anecdotal case report that described a young man who presented with extensive multiple intestinal perforations and a papular skin rash. Köhlmeier-Degos disease represents a unique vasculopathy targeting both the microvasculature and the arterial system. One of its most characteristic features is reflected by the discrete multifocal depressed porcelain lesions involving the skin and gastrointestinal tract. The pathological findings are striking and can be broadly categorized into those that are vascular in nature versus extravascular matrix production in the context of extensive extravascular hyaluronic acid and collagen deposition. A dynamic evolutionary morphology is observed not only clinically but also histologically. The microvascular alterations are particularly evident in the skin and are characterized by endothelial cell necrosis with subsequent endothelial cell detachment accompanied by intraluminal fibrin deposition, defining a thrombogenic microangiopathy that in later stage lesions is typically pauci-inflammatory. The arterial lesions are very distinctive and include significant neointimal proliferation with vascular luminal occlusion by amorphous plugs of collagen intimately admixed with platelets. Pathogenetically enhanced type I interferon signaling and endothelial cell injury mediated by the membranolytic attack complex (ie, C5b-9) are key in the evolution of the thrombotic microvascular and obliterative fibrosing arteriopathic changes. We describe a case of Köhlmeier-Degos disease that developed in the setting of tumor necrosis factor (TNF)-alpha inhibitor therapy with the drug golimumab. The clinical features, light microscopic findings, and a pathophysiologic paradigm based on the critical role of TNF-alpha in controlling the type I interferon response are discussed.
Asunto(s)
Interferón Tipo I , Papulosis Atrófica Maligna , Factor de Necrosis Tumoral alfa , Humanos , Papulosis Atrófica Maligna/patología , Masculino , Interferón Tipo I/efectos adversos , Interferón Tipo I/metabolismo , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Enfermedad IatrogénicaAsunto(s)
Papulosis Atrófica Maligna , Enfermedades del Pene , Úlcera Cutánea , Humanos , Masculino , Enfermedades del Pene/diagnóstico , Enfermedades del Pene/patología , Úlcera Cutánea/diagnóstico , Úlcera Cutánea/patología , Úlcera Cutánea/etiología , Papulosis Atrófica Maligna/diagnóstico , Papulosis Atrófica Maligna/patología , Papulosis Atrófica Maligna/complicaciones , Persona de Mediana Edad , Dolor/etiología , Dolor/diagnósticoRESUMEN
BACKGROUND: Atrophic papulosis (Köhlmeier-Degos disease, Degos disease) is a rare thrombo-obliterative microangiopathy of unknown pathogenesis. It usually affects people between the ages of 20 and 50. However, it can occur at any age. The condition is considered uncommon in children. OBJECTIVE: Clinical characterization of paediatric patients with atrophic papulosis. METHODS: Single-centre prospective cohort study with data derived from the international Degos Disease Registry collected between 2000 and 2021. RESULTS: Among 96 registered patients with atrophic papulosis fulfilling the criteria, 19 were aged 0 to completed 17 years at the time of onset. The median age at the time of onset was 5 years, ranging from 0 to 1 years for girls to 8 years for boys. In contrast to adult patients (male-to-female ratio 1:2.2), there was a male predominance in paediatric patients with a male-to-female ratio of 1.7:1. Systemic involvement, in particular gastrointestinal, central nervous system and cardiac, was more frequent in children than in adult patients. There were no statistically significant differences between family history, multisystem involvement, mortality and median survival time in the two groups. CONCLUSIONS: Atrophic papulosis has some distinct features in the paediatric population. It presents an important and still under-recognized problem. Therefore, it is mandatory to pay attention to the typical skin lesions in combination with neurological or gastrointestinal symptoms in order to make a prompt and accurate diagnosis.
Asunto(s)
Enfermedades del Tejido Conjuntivo , Papulosis Atrófica Maligna , Enfermedades de la Piel , Adulto , Humanos , Masculino , Niño , Femenino , Adolescente , Adulto Joven , Persona de Mediana Edad , Preescolar , Papulosis Atrófica Maligna/diagnóstico , Papulosis Atrófica Maligna/patología , Estudios Transversales , Estudios Prospectivos , Enfermedades de la Piel/patología , AtrofiaRESUMEN
Degos disease, also termed malignant atrophic papulosis, is a rare systemic vaso-occlusive disorder, seldom reported in the pediatric population. The pathognomonic skin lesion in Degos disease is a papule with an atrophic porcelain-white center with an erythematous, telangiectatic rim. The benign form of the disease remains limited to the skin, whereas, in others, it progresses to thrombotic vasculopathy in multiple organs including the gastrointestinal, cardiorespiratory, and central nervous systems, with a high mortality rate. We present a rare case of Degos disease in an adolescent female, presenting as acute renal failure secondary to thrombotic vasculopathy, with the characteristic skin lesion distinctively seen on dermoscopy.
Asunto(s)
Lesión Renal Aguda , Papulosis Atrófica Maligna , Adolescente , Humanos , Niño , Femenino , Papulosis Atrófica Maligna/complicaciones , Papulosis Atrófica Maligna/diagnóstico , Papulosis Atrófica Maligna/patología , Piel/patología , Atrofia/complicaciones , Atrofia/patología , Eritema/patología , Enfermedades Raras/complicaciones , Enfermedades Raras/patología , Lesión Renal Aguda/etiología , Lesión Renal Aguda/complicacionesRESUMEN
BACKGROUND: Atrophic papulosis (AP) is a rare obliterating vasculopathy characterized by specific skin lesions. The etiology and the pathophysiology of the disease remain unclear. The treatment is still empirical, while the malignant form of the disease is associated with a poor prognosis. SUMMARY: The underlying pathogenesis of AP includes three mechanisms with vasculopathy, coagulopathy, and endothelial dysfunction. Benign and malignant forms of AP are described. The benign form is confined to the skin. The pathognomonic skin lesions evolve over time and are large papules with an atrophic porcelain-white center and an erythematous rim. However, systemic involvement can occur months or years after the initial skin features. In this latter case, the associated mortality is very high with a mortality rate of over 65% in some series. Gastrointestinal involvement and central nervous system infarctions are the most frequent causes of death. Treatment is empirical with the use of antiplatelet therapy, anticoagulants, steroids, intravenous immunoglobulins, and immunosuppressive agents. Recent evidence shows that eculizumab, a complement inhibitor, is the most effective therapy in malignant AP with gastrointestinal involvement of the disease and should be combined with treprostinil to prevent relapse.
Asunto(s)
Papulosis Atrófica Maligna , Humanos , Papulosis Atrófica Maligna/complicaciones , Papulosis Atrófica Maligna/diagnóstico , Papulosis Atrófica Maligna/patología , Piel/patología , Eritema , InmunosupresoresRESUMEN
BACKGROUND: Although the merely cutaneous, benign form of the extremely rare disease atrophic papulosis (Köhlmeier-Degos disease) may occasionally develop into the systemic, malignant form with time, it is unclear whether it exhibits any systemic characteristics. OBJECTIVE: To determine whether benign atrophic papulosis exhibits inflammatory and thrombo-occlusive signals and to classify it according to the Chapel-Hill classification of vasculitis. METHODS: In a monocentric, controlled study, levels of cytokines (IL-1ß, IL-6, IL-8, IFNγ, MCP-1, VEGF, TNFα, TGF-ß1), antiphospholipid antibodies (cardiolipin IgG/A/M, cardiolipin IgG, cardiolipin IgM, ß2-glycoprotein IgG/A/M, phosphatidyl choline, phosphatidyl serine, phosphatidyl inositol, phosphatidyl ethanolamine and sphingomyelin A), antibodies against proteinase-3 IgG and myeloperoxidase IgG, antinuclear antibodies and extractable nuclear antigen were assessed in blood samples of six benign atrophic papulosis patients and six age- and sex-matched healthy controls. RESULTS: IL-8 was only detectable in patients' serum. VEGF was reduced and cardiolipin IgG/A/M and ß2-glycoprotein antibodies were increased in the patients' group. ANA were only detected in three patients, and ENA were negative throughout. No differences were detected between the other investigated markers. CONCLUSIONS: This is the first study evaluating systemic inflammatory and thrombo-occlusive vessel signalling in benign atrophic papulosis and provides evidence of a non-antineutrophil cytoplasmatic antibodies immune-complex small vessel vasculitis according to the Chapel-Hill classification. These findings corroborate its systemic character despite the apparent missing involvement of systemic organs.
Asunto(s)
Enfermedades del Tejido Conjuntivo , Papulosis Atrófica Maligna , Vasculitis , Anticuerpos Antinucleares , Anticuerpos Antifosfolípidos , Antígenos Nucleares , Atrofia , Cardiolipinas , Etanolaminas , Humanos , Inmunoglobulina G , Inmunoglobulina M , Inflamación , Interleucina-6 , Interleucina-8 , Papulosis Atrófica Maligna/complicaciones , Papulosis Atrófica Maligna/patología , Péptido Hidrolasas , Peroxidasa , Fosfatidilcolinas , Fosfatidilinositoles , Fosfatidilserinas , Esfingomielinas , Factor de Crecimiento Transformador beta1 , Factor de Necrosis Tumoral alfa , Factor A de Crecimiento Endotelial VascularRESUMEN
BACKGROUND: Atrophic papulosis is a very rare vascular disease of unknown pathogenesis, mostly described by case reports. OBJECTIVE: To assess demographic data and prognosis in patients with atrophic papulosis. METHODS: A single-centre study was performed on a series of 105 patients with atrophic papulosis, diagnosed 2000-2021. Patients were referred and diagnosed at the evaluation centre and patients' clinical data were provided by the Degos Support Network and evaluated by the authors for confirming the diagnosis of skin lesions and fulfilling the diagnostic criteria for a malignant subset. A unique set of variables were collected from all patients. RESULTS: The mean age of disease onset was 33.3 ± 18.3 years and the male-to-female ratio was 1:1.6. The family history rate was 8.1%. The classification into a benign, merely cutaneous disease (benign atrophic papulosis), and malignant atrophic papulosis, associating cutaneous and visceral lesions was confirmed due to their striking prognostic difference. Benign atrophic papulosis was detected in 41% of the patients with no deaths occurring throughout the follow-up period (median 3.00 years; range 0.13-23). Malignant atrophic papulosis was reported in 59% of patients with 47.5% multisystemic involvement and a median skin lesion onset to systemic symptoms duration of 0.54 years (-6 to 20). The gastrointestinal tract and central nervous system were equally involved; however, the neurological involvement-caused death rate was slightly higher. The disease-specific mortality rate of malignant atrophic papulosis was 22.6%. CONCLUSIONS: Atrophic papulosis presents with a striking prognostic difference of benign - merely cutaneous - involvement or quickly developing - into less than 1 year - malignant subset, associating cutaneous and visceral lesions and multiorgan involvement in 1/2 of the patients, which leads to premature, disease-specific mortality in 1/4 of the cases. Central nervous system and gastrointestinal tract complications are the major reasons for disease-specific death. Over the years, the diagnosis of severe nervous system involvement has become more common.
Asunto(s)
Enfermedades del Tejido Conjuntivo , Enfermedades Gastrointestinales , Papulosis Atrófica Maligna , Enfermedades de la Piel , Adolescente , Adulto , Atrofia/patología , Estudios Transversales , Femenino , Humanos , Masculino , Papulosis Atrófica Maligna/diagnóstico , Papulosis Atrófica Maligna/patología , Persona de Mediana Edad , Piel/patología , Enfermedades de la Piel/patología , Adulto JovenRESUMEN
INTRODUCTION: Kohlmeier-Degos (K-D) disease is a rare obliterative vasculopathy that can present as a benign cutaneous form or with potentially malignant systemic involvement. The gastrointestinal tract is most frequently involved in systemic disease and mortality is often related to bowel perforations. Herein, we provide information to providers and patients regarding gastrointestinal K-D symptomology, pathology, treatment, and diagnosis, with a focus on the importance of timely diagnostic laparoscopy. We present three new cases of gastrointestinal K-D to highlight varying disease presentations and outcomes. BODY: Based on reviewed reports, perforation is preceded by at least one gastrointestinal symptom: abdominal pain/cramping, anorexia/weight loss, vomiting, diarrhea, nausea, gastrointestinal bleeding, obstipation, constipation, and abdominal fullness. Perforation most commonly occurs in the small intestine and often results in sepsis and death. Although underutilized, laparoscopy is the most sensitive and specific diagnostic technique, demonstrating serosal porcelain plaques similar to those on the skin and characteristic for K-D. The combination of eculizumab and treprostinil is presently the most effective treatment option for gastrointestinal K-D. The pathology of gastrointestinal K-D is characterized by an obliterative intimal arteriopathy eventuating in occlusive acellular deposits of mucin and collagen along with an extravascular pauci-cellular sclerosing process resembling scleroderma confined to the subserosal fat. C5b-9 and interferon-alpha are both expressed in all caliber of vessels in the affected intestine. While C5b-9 blockade does not prevent the intimal expansion, enhanced type I interferon signaling is likely a key determinant to intimal expansion by, causing an influx of monocytes which transdifferentiate into procollagen-producing myofibroblast-like cells. CONCLUSION: Prompt laparoscopic evaluation is necessary in any K-D patient with an abdominal symptom to facilitate diagnosis and treatment initiation, as well as to hopefully decrease mortality. Those with gastrointestinal K-D should start on eculizumab as soon as possible, as onset of action is immediate.
Asunto(s)
Enfermedades Gastrointestinales , Papulosis Atrófica Maligna , Complejo de Ataque a Membrana del Sistema Complemento , Enfermedades Gastrointestinales/diagnóstico , Enfermedades Gastrointestinales/patología , Humanos , Papulosis Atrófica Maligna/diagnóstico , Papulosis Atrófica Maligna/patología , Piel/patologíaRESUMEN
Malignant atrophic papulosis (MAP), or systemic Degos disease, is an obliterative vasculopathy of unknown origin, characterized by erythematous papules found on the skin, central nervous system (Neuro-MAP) and gastrointestinal tract. Neurological involvement occurs in approximately 20% of systemic cases, is progressive and largely fatal. It can be described in two forms: 1) the parenchymal presenting with meningoencephalitis and meningomyelitis and 2) the neurovascular presenting with large cerebral infarcts, intracranial and subarachnoid hemorrhage, subdural hematoma and venous sinus thrombosis. Predilection to subdural hematoma or hygroma is characteristic for neurological involvement in MAP in comparison to other vasculpathies and vasculitides. Peripheral nervous system manifestations are less common and include polyradiculopathy, neuropathy, and myopathy. CSF analysis usually shows mild to moderate pleocytosis, increased protein content, and normal glucose. Brain MRI may reveal cortical, subcortical and deep white matter ischemic lesions with possible nodular, leptomeningeal, dural, or ependymal enhancement. Spinal cord MRI may reveal patchy lesions from the periphery to the center or cord atrophy in progressive course. Neurological involvement in MAP has a grave prognosis. The interval from onset of papulosis to death averages two years in patients with neurological involvement. There is no confirmed treatment for MAP but there are promising reports with eculizumab and treprostinil.
Asunto(s)
Papulosis Atrófica Maligna , Atrofia/patología , Hematoma Subdural , Humanos , Papulosis Atrófica Maligna/complicaciones , Papulosis Atrófica Maligna/patología , Pronóstico , Piel/patologíaAsunto(s)
Carcinoma de Células Renales/complicaciones , Neoplasias Renales/complicaciones , Papulosis Atrófica Maligna/diagnóstico , Carcinoma de Células Renales/diagnóstico por imagen , Carcinoma de Células Renales/secundario , Humanos , Neoplasias Renales/diagnóstico por imagen , Masculino , Papulosis Atrófica Maligna/complicaciones , Papulosis Atrófica Maligna/patología , Persona de Mediana Edad , Piel/patología , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Degos disease is a rare vascular disorder with a cutaneous-limited form, benign atrophic papulosis (BAP), and a systemic variant, malignant atrophic papulosis (MAP). Despite the poor prognosis of MAP, no study has established features associated with systemic disease. OBJECTIVES: The aims of this systematic review were to: (1) summarize clinical features and treatments implemented for patients with MAP and BAP (2) identify clinical and laboratory factors associated with the development of MAP, compared to BAP. METHODS: We systematically searched MEDLINE and Embase from inception to April 2020. Demographic and clinical features of Degos patients were presented descriptively; multivariable logistic regression was performed to identify associations with MAP. RESULTS: We identified 99 case studies, comprising 105 patients. MAP (64%) had a 2.15 year median survival time from cutaneous onset, most often with gastrointestinal or central nervous system involvement. We found that elevations in either of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) were associated with systemic involvement (OR 2.27, p = 0.023). Degos secondary to an autoimmune connective tissue disease was found to be inversely associated with MAP (OR 0.08, p = 0.048). CONCLUSIONS: Elevated ESR or CRP is associated with MAP and may be a predictor of systemic involvement for patients with Degos disease. In addition, secondary Degos disease is associated with a favourable prognosis. Clinicians should be aware of the differences between primary and secondary Degos and the utility of ESR or CRP in identifying disease evolution to systemic involvement. The utility of ESR and CRP to identify systemic involvement should be further explored.
Asunto(s)
Enfermedades del Tejido Conjuntivo , Papulosis Atrófica Maligna , Atrofia , Enfermedades del Tejido Conjuntivo/patología , Humanos , Laboratorios , Papulosis Atrófica Maligna/diagnóstico , Papulosis Atrófica Maligna/patología , Piel/patologíaAsunto(s)
Ataxia Cerebelosa/genética , Proteínas del Ojo/genética , Predisposición Genética a la Enfermedad , Papulosis Atrófica Maligna/genética , Proteínas de la Membrana/genética , Adolescente , Adulto , Ataxia Cerebelosa/complicaciones , Ataxia Cerebelosa/patología , Femenino , Humanos , Ictiosis/genética , Queratosis/genética , Queratosis/patología , Masculino , Papulosis Atrófica Maligna/patología , Columna Vertebral/patología , Adulto JovenRESUMEN
Antiphospholipid syndrome (APS) is an acquired thrombophilic disorder in which autoantibodies are produced against a variety of phospholipids and phospholipid-binding proteins. The purpose of this article is to review cutaneous findings in patients with APS diagnosis. An overview regarding prevalence, description, pathogenesis and histopathology, are described for cutaneous manifestations of APS.
Asunto(s)
Anticuerpos Antifosfolípidos/inmunología , Síndrome Antifosfolípido/patología , Livedo Reticularis/patología , Enfermedades de la Piel/patología , Vasculitis/patología , Adulto , Anciano , Anetodermia/etiología , Anetodermia/patología , Anticuerpos Anticardiolipina/inmunología , Síndrome Antifosfolípido/diagnóstico , Síndrome Antifosfolípido/epidemiología , Síndrome Antifosfolípido/inmunología , Biopsia , Femenino , Gangrena/etiología , Gangrena/patología , Humanos , Livedo Reticularis/diagnóstico , Livedo Reticularis/etiología , Livedo Reticularis/inmunología , Inhibidor de Coagulación del Lupus/inmunología , Masculino , Papulosis Atrófica Maligna/etiología , Papulosis Atrófica Maligna/patología , Persona de Mediana Edad , Necrosis/diagnóstico , Necrosis/etiología , Prevalencia , Enfermedades de la Piel/inmunología , Úlcera/patología , Vasculitis/etiologíaRESUMEN
Vascular occlusion has multiple, diverse clinical manifestations, some of which can have grave consequences for patients. It also has a wide variety of causes, including thrombi, which we recently addressed in partI of this review. In this second part, we look at additional causes of vascular occlusion.
Asunto(s)
Trastornos de la Coagulación Sanguínea/complicaciones , Embolia/complicaciones , Enfermedades Cutáneas Vasculares/etiología , Anticoagulantes/efectos adversos , Síndrome Antifosfolípido/complicaciones , Síndrome Antifosfolípido/patología , Calcifilaxia/complicaciones , Calcifilaxia/patología , Cocaína/efectos adversos , Femenino , Cuerpos Extraños/complicaciones , Cuerpos Extraños/patología , Humanos , Isquemia/etiología , Isquemia/patología , Levamisol/efectos adversos , Livedo Reticularis/etiología , Livedo Reticularis/patología , Masculino , Papulosis Atrófica Maligna/patología , Necrosis , Neoplasias/complicaciones , Neoplasias/patología , Paraproteinemias/complicaciones , Paraproteinemias/patología , Piel/irrigación sanguínea , Enfermedades Cutáneas Vasculares/inducido químicamente , Enfermedades Cutáneas Vasculares/patología , Úlcera Cutánea/etiología , Úlcera Cutánea/patología , Síndrome de Sneddon/patologíaRESUMEN
Malignant atrophic papulosis (Degos disease) is an unusual thrombotic microangiopathy of uncertain etiology. The disease characteristically involves the skin and internal organs, with nervous system involvement more common in children. We present a case with diverse neurological manifestations including cranial nerve palsies, gait instability, and urinary incontinence. The patient also developed white papular lesions on her lower extremities and back. Magnetic resonance imaging (MRI) demonstrated progressive intracranial and spinal abnormalities. Despite treatment with numerous biologic agents, the patient had persistent clinical deterioration and expired one month after admission. We highlight the extensive neurologic manifestations of Degos disease correlated with neuroradiological imaging and pathological features. Nervous system involvement in Degos disease requires careful neurologic and dermatologic exam with central nervous system (CNS) magnetic resonance imaging to distinguish it from non-organic etiologies of similar symptoms.
Asunto(s)
Imagen por Resonancia Magnética/métodos , Papulosis Atrófica Maligna/diagnóstico por imagen , Papulosis Atrófica Maligna/patología , Enfermedades del Sistema Nervioso/etiología , Microangiopatías Trombóticas/patología , Adolescente , Anticuerpos Monoclonales Humanizados/uso terapéutico , Factores Biológicos/uso terapéutico , Sistema Nervioso Central/diagnóstico por imagen , Sistema Nervioso Central/patología , Enfermedades de los Nervios Craneales/diagnóstico , Enfermedades de los Nervios Craneales/etiología , Progresión de la Enfermedad , Quimioterapia Combinada , Resultado Fatal , Femenino , Trastornos Neurológicos de la Marcha/diagnóstico , Trastornos Neurológicos de la Marcha/etiología , Humanos , Papulosis Atrófica Maligna/complicaciones , Papulosis Atrófica Maligna/tratamiento farmacológico , Enfermedades del Sistema Nervioso/diagnóstico , Nitrilos , Pirazoles/uso terapéutico , Pirimidinas , Piel/patología , Microangiopatías Trombóticas/etiología , Incontinencia Urinaria/diagnóstico , Incontinencia Urinaria/etiologíaRESUMEN
The small guanosine triphosphatase Rho and its target Rho kinase are involved in a heterogeneous spectrum of cellular activities, many of which are integral to cytoskeletal organization. Furthermore, the Rho kinases result in NF kappa beta activation and hence the induction of various pro-inflammatory cytokines including TNF-alpha, IL-1B and IL-6. ROCK2 is a downstream protein, whose expression is indicative of Rho Kinase activation. Given the diverse effects of Rho-kinase, including a potentially critical role in augmenting inflammation, ROCK2 expression was examined in biopsies of select autoimmune connective tissue diseases as compared to control diagnoses. Select cases of lupus erythematosus, dermatomyositis, autoimmune sclerodermoid disorders and Kohlmeier-Degos disease (a distinctive vasculopathy that occurs in the other aforesaid conditions but also as a forme fruste microvascular and arteriopathic syndrome) were studied. Control biopsies included normal skin and cutaneous inflammatory conditions unrelated to collagen vascular disease/autoimmune disease. We found ROCK2 expression significantly increased in biopsies of lupus erythematosus, dermatomyositis, scleroderma and Kohlmeier-Degos disease. A pattern emerged of consistent marked ROCK2 upregulation in endothelium and variable expression in inflammatory cells and epithelium. While expression was undetectable in normal skin, it was found in inflamed skin unrelated to specific autoimmune disease. The staining pattern could approach that seen in study group cases but was less pronounced and preferentially upregulated in the endothelium, with a lesser extent of staining in the epidermis and inflammatory cells. Rho kinase is a driving factor in diverse cutaneous diseases especially autoimmune disease and Kohlmeier-Degos disease. This significantly upregulated pathway defines a potential target for biologic therapy.